The combination of the AKT inhibitor capivasertib (AZD5363) with the MCL1 inhibitor AZD5991 was one of the most selective combinations, active in only 2 of 41 cancer types (Supplementary Fig. S12B). The gene discussed is AKT1; the disease is cancer.